Literature DB >> 22795376

Role of testosterone in managing advanced prostate cancer.

Kyle O Rove1, Frans M Debruyne, Bob Djavan, Leonard G Gomella, Hari K Koul, M Scott Lucia, Daniel P Petrylak, Neal D Shore, Nelson N Stone, E David Crawford.   

Abstract

Androgen deprivation therapy is frequently used to treat patients with advanced prostate cancer. New therapies for metastatic castration-resistant prostate cancer have drawn increased attention to serum and intratumoral testosterone levels. The present review examines the role of testosterone in prostate cancer progression, discusses the nuances and potential pitfalls in measuring serum testosterone using available assays, and summarizes current data relevant to the arguments for and against achieving and maintaining the lowest possible testosterone levels during androgen deprivation therapy, including the adverse effects of such treatment. Incorporating this information, we have made recommendations incorporating testosterone evaluation and its effect on the clinical decision-making process.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22795376     DOI: 10.1016/j.urology.2012.05.006

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  5 in total

1.  Identifying Drug Interactions between Enzalutamide and Complementary Alternative Medications in a Patient with Metastatic Prostate Cancer: A Case Report.

Authors:  Thomas Brownlee; Colleen Olson; Michelle Deschamps
Journal:  Can J Hosp Pharm       Date:  2018-08-28

Review 2.  Maximal testosterone suppression in prostate cancer--free vs total testosterone.

Authors:  Kyle O Rove; E David Crawford; Massimo Perachino; Juan Morote; Laurence Klotz; Paul H Lange; Gerald L Andriole; Alvin M Matsumoto; Samir S Taneja; Mario A Eisenberger; Leonardo O Reis
Journal:  Urology       Date:  2014-04-06       Impact factor: 2.649

3.  Biodistribution and Efficacy of Low Temperature-Sensitive Liposome Encapsulated Docetaxel Combined with Mild Hyperthermia in a Mouse Model of Prostate Cancer.

Authors:  Ashish Ranjan; Compton J Benjamin; Ayele H Negussie; Saurin Chokshi; Paul H Chung; Dmitry Volkin; Nitin Yeram; W Marston Linehan; Matthew R Dreher; Peter A Pinto; Bradford J Wood
Journal:  Pharm Res       Date:  2016-06-24       Impact factor: 4.200

4.  Accuracy of serum luteinizing hormone and serum testosterone measurements to assess the efficacy of medical castration in prostate cancer patients.

Authors:  Juan Morote; Imma Comas; Roser Ferrer; Jacques Planas; Anna Celma; Lucas Regis
Journal:  J Biomed Sci       Date:  2017-10-22       Impact factor: 8.410

Review 5.  Definition of Castrate Resistant Prostate Cancer: New Insights.

Authors:  Juan Morote; Adriana Aguilar; Jacques Planas; Enrique Trilla
Journal:  Biomedicines       Date:  2022-03-17
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.